Skip to main content
. 2020 May 4;11:2189. doi: 10.1038/s41467-020-15768-x

Fig. 1. Study overview.

Fig. 1

We combined data from six tumour sequencing studies of TGCT, performing small variant, copy number and tumour evolution analyses to define the molecular hallmarks of TGCT and their response to platinum-based therapies. RES: resistant, SEN: sensitive, UNS: unselected, PRI: primary, MET: metastasis, WES: whole exome sequencing, PNL: gene panel sequencing, MIP: molecular inversion probe, ARY: genotyping array, TMB: tumour mutation burden.